Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells.

Search TravelDoctorOnline

Authors: Kim J,Yip ML,Shen X,Li H,Hsin LY,Labarge S,Heinrich EL,Lee W,Lu J,Vaidehi N,
Address: Department of Surgery, City of Hope, Duarte, California, United States of America. jokim@coh.org
Journal: PLoS One.


Publication: 2012;7(2):e31004. doi: 10.1371/journal.pone.0031004. Epub 2012 Feb 3.

abstract

Despite recent advances in targeted therapies, patients with pancreatic adenocarcinoma continue to have poor survival highlighting the urgency to identify novel therapeutic targets. Our previous investigations have implicated chemokine receptor CXCR4 and its selective ligand CXCL12 in the pathogenesis and progression of pancreatic intraepithelial neoplasia and invasive pancreatic cancer; hence, CXCR4 is a promising target for suppression of pancreatic cancer growth. Here, we combined in silico structural modeling of CXCR4 to screen for candidate anti-CXCR4 compounds with in vitro cell line assays and identified NSC56612 from the National Cancer Institute's (NCI) Open Chemical Repository Collection as an inhibitor of activated CXCR4. Next, we identified that NSC56612 is structurally similar to the established anti-malarial drugs chloroquine and hydroxychloroquine. We evaluated these compounds in pancreatic cancer cells in vitro and observed specific antagonism of CXCR4-mediated signaling and cell proliferation. Recent in vivo therapeutic applications of chloroquine in pancreatic cancer mouse models have demonstrated decreased tumor growth and improved survival. Our results thus provide a molecular target and basis for further evaluation of chloroquine and hydroxychloroquine in pancreatic cancer. Historically safe in humans, chloroquine and hydroxychloroquine appear to be promising agents to safely and effectively target CXCR4 in patients with pancreatic cancer.



Related Articles
Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
J Transl Med. 2012
Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL, Lee W, Lu J, Lowy AM, Kim J. J Transl Med. 2012 Apr 2; 10:68. Epub 2012 Apr 2.
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Br J Cancer. 2010
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. Br J Cancer. 2010 Nov 23; 103(11):1671-9. Epub 2010 Nov 2.
The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia.
Gut. 2008
The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia.
Thomas RM, Kim J, Revelo-Penafiel MP, Angel R, Dawson DW, Lowy AM. Gut. 2008 Nov; 57(11):1555-60. Epub 2008 Jul 29.
Review Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Expert Rev Anticancer Ther. 2011
Review Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA, Stewart DJ, Wald O, Peled A. Expert Rev Anticancer Ther. 2011 Apr; 11(4):621-30.
Review The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Curr Med Chem. 2011
Review The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L, Baldari CT. Curr Med Chem. 2011; 18(4):497-512.
Small molecule inhibitors of CXCR4.
Theranostics. 2013
Small molecule inhibitors of CXCR4.
Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Theranostics. 2013; 3(1):47-75. Epub 2013 Jan 15.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.